Compositions and methods for detecting mutations in JAK2 nucleic acid

Patent metadata

Field	Value
Publication number	US-12378609-B2
Application number	US-202117204227-A
Country	US
Kind code	B2
Filing date	Mar 17, 2021
Priority date	Oct 31, 2008
Publication date	Aug 5, 2025
Grant date	Aug 5, 2025

Abstract

The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.

First claim

What is claimed is:

1. A method for detecting one or more mutant JAK2 nucleic acids, comprising:
(a) contacting a sample with one or more detectably labeled nucleic acid probes, wherein at least one probe specifically hybridizes to an adenine to thymine mutation at a nucleotide position 2091 of SEQ ID NO: 1; and
(b) detecting one or more mutant JAK2 nucleic acids when a hybrid is formed between the one or more detectably labeled nucleic acid probes and the one or more mutant JAK2 nucleic acids, wherein the one or more mutant JAK2 nucleic acids is not a total exon 14 deletion corresponding to nucleotides 2271-2358 of SEQ ID NO: 1.

2. The method of claim 1 , further comprising amplification of a JAK2 nucleic acid containing the mutation.

3. The method of claim 2 , wherein the amplification uses a primer pair consisting of a forward primer having a nucleotide sequence set forth in SEQ ID NO: 6 and a reverse primer having a nucleotide sequence set forth in SEQ ID NO:7.

4. The method of claim 2 , further comprising sequencing an amplification product.

5. The method of claim 1 , wherein at least a first mutant JAK2 nucleic acid detected in (b) is the adenine to thymine mutation at a nucleotide position 2091 of SEQ ID NO: 1.

6. The method of claim 5 , wherein at least a second mutant JAK2 nucleic acid detected in (b) is selected from c2035t, t2127c, t2133c, c2180t, g2185t, g2185a, g2193t, t2194c, c2204t, g2205a, g2205c, c2229t, c2253a, c2266t, c2312a, t2365c, and a2427g.

7. The method of claim 1 , wherein the JAK2 nucleic acid is mRNA.

8. The method of claim 1 , wherein the sample is selected from the group consisting of blood, serum, and plasma.

9. The method of claim 1 , wherein the sample is obtained from a human subject.

10. The method of claim 9 , wherein the human subject is suspected of having a hematopoietic disease.

11. The method of claim 10 , wherein the hematopoietic disease is a myeloproliferative disease.

12. The method of claim 11 , wherein the myeloproliferative disease is selected from the group consisting of polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, and unclassified myeloproliferative disease.

Assignees

• Quest Diagnostics Invest Llc

Inventors

• Albitar Maher
• Ma Wanlong

Classifications

• C12Q1/6869

  Methods for sequencing · CPC title

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• G01N2800/22

  Haematology · CPC title

• G01N2333/91205

  Phosphotransferases in general · CPC title

• G01N33/573

  for enzymes or isoenzymes · CPC title